T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia

T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia

Background Acute myeloid leukemia (AML) remains one of the most challenging hematological malignancies. Despite progress in therapeutics, majority of patients succumb to this neoplasm. CD33 is a proven therapeutic target, given its expression on most AML cells. Almost all anti-CD33 antibodies target...

Full description

Bibliographic Details
Main Authors: Madelyn Espinosa-Cotton, Sayed Shahabuddin Hoseini, Hong-fen Guo, Nai-Kong V Cheung, Yi Feng, Mallika Vadlamudi, Hoa Tran, Irene Cheung
Format: Article
Language:English
Published: BMJ Publishing Group 2021-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/5/e002509.full

Internet

https://jitc.bmj.com/content/9/5/e002509.full

Similar Items